Recombinant Human UBE2K (N-6His, SUMO tag)

Description

EnkiLife provides the Recombinant Human UBE2K (N-6His, SUMO tag) protein,aslo know as Ubiquitin-Conjugating Enzyme E2 K,Huntingtin-Interacting Protein 2,HIP-2,Ubiquitin Carrier Protein,Ubiquitin-Conjugating Enzyme E2-25 kDa,Ubiquitin-Conjugating Enzyme E2(25K),Ubiquitin-Conjugating Enzyme E2-25K,Ubiquitin-Protein Ligase,UBE2K,HIP2,LIG, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Ubiquitin-Conjugating Enzyme E2 K is produced by our E.coli expression system and the target gene encoding Met1-Asn200 is expressed with a 6His, SUMO tag at the N-terminus.Accession:P61086. Expression Host:E.coli.Species:Human.Predicted Molecular Mass:34.5 KDa. Background:Ubiquitin-Conjugating Enzyme E2 K (UBE2K) belongs to the E2 Ubiquitin-Conjugating Enzyme family. UBE2K is highly expressed in the brain, with highest levels found in cortex and striatum, and at lower levels in cerebellum and brainstem. UBE2K may mediate foam cell formation by the suppression of apoptosis of lipid-bearing macrophages through ubiquitination and subsequence degradation of p53/TP53. UBE2K is associated with the selective degradation of short-lived and abnormal proteins, such as the endoplasmic reticulum-associated degradation (ERAD) of misfolded lumenal proteins. In addition, UBE2K is involved in Alzheimers disease, Huntingtons disease and antigen processing through its interaction with huntingtin, and MHC-heavy chain proteins.